A two-stage design for phase II trials with time-to-event endpoint using restricted follow-up

In phase II oncology trials, the use of new cytostatic drugs raises some questions regarding the endpoint. Time-to-event endpoints such as Progression-Free Survival have been recommended and led to new designs. In 2003, Case and Morgan proposed a design based on the comparison of the cumulative haza...

Descripción completa

Detalles Bibliográficos
Autores principales: Belin, Lisa, De Rycke, Yann, Broët, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898579/
https://www.ncbi.nlm.nih.gov/pubmed/29696201
http://dx.doi.org/10.1016/j.conctc.2017.09.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898579/
https://www.ncbi.nlm.nih.gov/pubmed/29696201
http://dx.doi.org/10.1016/j.conctc.2017.09.010

Ejemplares similares